Skip to content
Is synthetic chemistry a gateway to inventing new drugs? Are there environmental benefits of creating synthetic compounds for psychedelic research.

Details

  • Main Stage
Date:
11/05/2022
Start Time:
12:00 pm
End Time:
12:40

Masha Ty

Corporate Growth, ACS Laboratory

Masha Ty has resolved major challenges in marketing, e-commerce, compliance, talent acquisition and brand activations for Fortune 500 companies. Now she brings that skillset to cannabis and psychedeli…

Dr. Amy Reichelt

Chief Innovation Officer, PurMinds Neuropharma

Dr. Amy Reichelt is a recognized leader in neuroscience, specializing in psychedelic drug development. She has 15 years of expertise in translational medicine spanning from molecules to mind, and is p…

Prof. Joseph Lichter, PhD

Chemistry Professor, Director of FIU Pre-Health Advising Program

Dr. Joseph Lichter is a professor in the Department of Chemistry and Biochemistry at Florida International University, where he also serves as director of the pre-health advising office. Dr. Lichter t…

Abraham Dreazen

CEO, IMIO Life

Abraham Dreazen, CEO & Founder of Nextage Therapeutics and IMIO Life, is a creative thinker and experienced architect with knowledge of concept design and design development. He is a serial entreprene…

Rick Doblin

Executive Director, MAPS

Rick Doblin, Ph.D., is the founder and executive director of the Multidisciplinary Association for Psychedelic Studies (MAPS). He received his doctorate in Public Policy from Harvard’s Kennedy School …

Adam Coape-Arnold

CEO / Founder, Cubed Biotech Inc

Adam B. Coape-Arnold is the CEO and Founder of Cubed Biotech Inc. He has a decade of experience owning and operating premium brands in the regulated industries of raw dairy, yogurt, and cannabis, with…

Get Recordings Now!

Easily access the recordings for your favorite Wonderland sessions, allowing you to revisit the discussions and insights shared by our visionary speakers.

Buy Now